Braintree Labs v. Appco Pharma: SUTAB® Patent Suit Dismissed Without Prejudice
Braintree Laboratories sued Appco Pharma in the New Jersey District Court alleging infringement of four patents covering its SUTAB® bowel-preparation tablet formulation. The case was voluntarily dismissed without prejudice under Rule 41(a)(1) just 97 days after filing, with each party bearing its own costs — leaving the door open for future enforcement.
SUTAB® Generic Entry Dispute Ends Without Merits Ruling
Braintree Laboratories, Inc. filed suit on June 13, 2025 in the U.S. District Court for the District of New Jersey against Appco Pharma, LLC, asserting infringement of four U.S. patents — US10143656B1, US11033498B2, US11382864B2, and US11638697B2 — all directed to its SUTAB® bowel-preparation product, a combination of sodium sulfate, magnesium sulfate, and potassium chloride in tablet form. The complaint was triggered by Appco’s proposed generic version of the same formulation, a pattern consistent with Hatch-Waxman ANDA litigation in the pharmaceutical sector.
The case was terminated on September 18, 2025, when Braintree (joined by co-plaintiff Sebela US Inc., named in the dismissal notice) filed a voluntary stipulation of dismissal without prejudice under Federal Rule of Civil Procedure 41(a)(1). Critically, the dismissal is without prejudice, meaning Braintree has not relinquished its infringement claims and may refile. Each party was ordered to bear its own attorneys’ fees and costs, suggesting the resolution did not involve a fee-shifting finding against either side.
A 97-day lifecycle without any substantive ruling is consistent with early-stage settlement negotiations, a licensing agreement, or a strategic pause — none of which are confirmed by the public record. The absence of a consent judgment or license disclosure means the commercial terms, if any exist, remain confidential. Appco’s ANDA status and any FDA approval timeline would be material factors in assessing whether this dismissal resolves the dispute or merely defers it.
Filing to Dismissed without Prejudice in 97 days
97-day lifespan — resolved before any substantive court rulings
Dismissed without prejudice: what Rule 41(a)(1) means for both parties
Rule 41(a)(1) voluntary dismissal — no merits adjudicated
Under Federal Rule of Civil Procedure 41(a)(1), a plaintiff may dismiss an action without a court order by filing a notice before the defendant serves an answer or a motion for summary judgment. This is a procedural exit, not a merits ruling. No finding of infringement, validity, or invalidity was made. The case closes on the docket, but the underlying patent claims remain legally intact and enforceable.
No merits rulingWithout prejudice preserves Braintree’s right to refile
A dismissal without prejudice does not bar Braintree from reasserting the same four patents against Appco in a future action. This contrasts with a dismissal with prejudice, which would permanently extinguish the claims. The public record does not indicate whether a settlement, license, or other agreement underpins this dismissal — that distinction is commercially significant but cannot be confirmed from the available filings.
Refile right preservedAppco avoids an adverse ruling — but uncertainty persists
Appco Pharma obtains no declaratory judgment of non-infringement or invalidity. While the immediate litigation threat is removed, the four SUTAB® patents remain valid and enforceable. Appco’s ability to launch its generic product without further legal challenge depends on factors not resolved by this dismissal — including any agreed licensing terms or FDA approval status that are not part of the public record.
No invalidity findingGeneric bowel prep market entry remains legally contested
The dismissal without prejudice signals the dispute over SUTAB® generic entry is unresolved at a substantive level. Companies developing or distributing sodium sulfate/magnesium sulfate/potassium chloride bowel prep formulations should treat all four asserted patents as active blocking risks. The 97-day resolution timeline and each-party-bears-own-costs clause are consistent with a negotiated arrangement, though no such arrangement is confirmed by public filings.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Braintree Laboratories, Inc. | Company | Pharmaceutical company — holder of SUTAB® bowel prep tablet patents US10143656B1 et al.Search in Eureka ↗ |
| Defendant | Appco Pharma, LLC | Company | Generic pharmaceutical company seeking to market a generic version of SUTAB® bowel prep tablets.Search in Eureka ↗ |
| Plaintiff counsel | BRADLEY ALAN SUITERS | Attorney | Counsel for Braintree Laboratories, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for Braintree Laboratories, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Braintree Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Katherine Ann Escanlar. | Attorney | Counsel for Appco Pharma, LLCSearch in Eureka ↗ |
| Defendant law firm | Saiber LLC | Law Firm | Representing Appco Pharma, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1), which permits a plaintiff to exit litigation as of right before the defendant has answered or moved for summary judgment — the earliest and cleanest procedural exit available. The ‘without prejudice’ qualifier is legally significant: it preserves Braintree’s entire cause of action. The each-party-bears-own-costs clause removes any fee-shifting implication but does not indicate a merits outcome. No court order was required, and no judicial determination was made on infringement, validity, or claim scope.
US10143656B1 and three further patents — SUTAB® bowel prep tablet formulation
The four asserted patents — US10143656B1, US11033498B2, US11382864B2, and US11638697B2 — cover formulations and methods relating to SUTAB®, a prescription bowel preparation product containing 1.479 g sodium sulfate, 0.225 g magnesium sulfate, and 0.188 g potassium chloride per tablet. The application numbers span from US15/669749 (filed 2017) through US17/347469 and US17/340973 (filed 2021), suggesting a portfolio built through continuation or continuation-in-part practice to extend protection across different claim scopes.
A four-patent portfolio of this structure is strategically significant in the Hatch-Waxman context: multiple patents covering a single branded product create overlapping layers of protection that a generic entrant must design around or challenge individually. The staggered filing dates suggest Braintree has actively prosecuted broader and narrower claim sets, potentially covering formulation, method of use, and dosing regimen aspects of SUTAB®. Any generic filer must assess each patent independently for invalidity and non-infringement arguments before an ANDA can safely proceed to launch.
Should you run an FTO against the SUTAB® patent portfolio?
Any company developing, manufacturing, or distributing a generic or follow-on sodium sulfate/magnesium sulfate/potassium chloride bowel preparation tablet should treat this case as a direct signal. Braintree has demonstrated willingness to enforce all four patents simultaneously, and the without-prejudice dismissal confirms it has not abandoned those claims. ANDA filers, contract manufacturers, and distributors all face potential exposure and should conduct a thorough freedom-to-operate analysis before any commercial step.
PatSnap Eureka’s FTO Search Agent can map the full claim scope of US10143656B1, US11033498B2, US11382864B2, and US11638697B2 against your proposed formulation, identify prosecution history estoppel risks, and surface related continuation applications that may not yet be asserted. Eureka also tracks ANDA litigation trends for bowel prep formulations, helping your team anticipate the enforcement posture of both Braintree Laboratories and Sebela US Inc. before committing to a launch timeline.
Run a freedom-to-operate analysis on US10143656B1 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA bowel prep patent infringement cases in U.S. District Courts
Cases involving Hatch-Waxman challenges to branded bowel preparation formulation patents in the New Jersey District Court and comparable federal venues.
What this case signals for the pharmaceutical bowel prep IP landscape
Four SUTAB® patents remain live enforcement tools; generic entrants face an unresolved patent thicket.
All four SUTAB® patents remain enforceable against future generic filers
No validity or infringement finding was made. Braintree retains the right to assert US10143656B1, US11033498B2, US11382864B2, and US11638697B2 against Appco or any other ANDA filer targeting the sodium sulfate/magnesium sulfate/potassium chloride bowel prep formulation. Generic developers should conduct updated FTO analysis across all four patent families before proceeding.
Rule 41(a)(1) exit in under 100 days suggests early commercial resolution
A voluntary dismissal this early — before answer, before claim construction, before any discovery — is a strong signal that the parties reached an understanding outside the courtroom. Whether that understanding is a license, a delayed-entry agreement, or simply a strategic pause is unknown from public filings, but the pattern is common in Hatch-Waxman ANDA disputes involving branded formulation patents.
Braintree v Appco — key questions answered
Braintree Laboratories filed a patent infringement suit against Appco Pharma in the New Jersey District Court on June 13, 2025, asserting four patents covering its SUTAB® bowel prep tablets. The case was voluntarily dismissed without prejudice under Rule 41(a)(1) on September 18, 2025, 97 days after filing, with each party bearing its own costs. No merits ruling was issued.
Braintree asserted four U.S. patents: US10143656B1 (App. No. US15/669749), US11033498B2 (App. No. US16/207800), US11382864B2 (App. No. US17/347469), and US11638697B2 (App. No. US17/340973). All four cover aspects of the SUTAB® sodium sulfate, magnesium sulfate, and potassium chloride bowel preparation tablet formulation.
A dismissal without prejudice under Rule 41(a)(1) does not extinguish Braintree’s claims. Braintree retains the full right to refile suit against Appco Pharma on the same four patents in the future. No validity or infringement determination was made, so the patents remain fully enforceable against Appco and any other party.
The complaint targets Appco’s proposed generic version of the SUTAB® formulation — a pattern consistent with Hatch-Waxman ANDA litigation, where a brand manufacturer sues upon receiving notice of a generic ANDA filing containing a Paragraph IV certification. The public case record does not explicitly confirm the ANDA filing details, but the product description and litigation structure are strongly consistent with that framework.
The public record does not disclose the reason for the 97-day voluntary dismissal. Common reasons in Hatch-Waxman patent suits include negotiated licensing or settlement agreements, delayed-entry arrangements, or a strategic decision to refile with amended claims or additional parties. The each-party-bears-own-costs clause and the absence of a consent judgment leave the underlying commercial rationale undisclosed.
PatSnap Eureka searches patents and litigation data to answer instantly.